Caribou Biosciences Shares Rise 4.1% as FDA Approves Lymphoma Trial
13 12월 2023 - 8:26AM
Dow Jones News
By Ben Glickman
Shares of Caribou Biosciences rose after the company's lymphoma
trial design was approved by the Food and Drug Administration.
The stock was up 4.1% to $5.88 in after-hours trading following
a 1.9% drop at Tuesday's close. Shares are down 10% this year.
The Berkeley, Calif.-based gene-editing pharmaceutical company
said it had received feedback from the FDA on its Phase 3 trial for
CB-010, a treatment for large B cell lymphoma.
The company plans to initiate its Phase 3 trial by the end of
2024.
The trial design includes platinum-based immunochemotherapy,
followed by high-dose chemotherapy and autologous stem cell
transplantation.
Chief Executive Rachel Haurwitz said the FDA feedback was "an
important step in advancing our lead therapy."
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 12, 2023 18:11 ET (23:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Caribou Biosciences (NASDAQ:CRBU)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Caribou Biosciences (NASDAQ:CRBU)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
